Publication: 4370

Publication: 4370

Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) After Progression on Prior Therapy (CABINET Trial): Updated Progression Free-Survival (PFS) Results by Blinded Independent Central Review (BICR) (Alliance)

DOI

URL

Google Scholar

Citation:: Annals of Oncology vol 35 (Supplement 2) S749

Meeting Instance:: ESMO 2024
Year:: 2024
Type:: Abstract
Sub type:: Oral
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epreprint

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882; U10CA180820 (ECOG-ACRIN), U10CA180868 (NRG), U10CA180888 (SWOG)

Corr. Author:
Authors:: Jennifer A Chan Susan Geyer Tyler Zemla Michael V Knopp Spencer Behr Sydney Pulsipher Jared Acoba Ardaman Shergill Edward M Wolin Thorvardur R Halfdanarson Bhavana Konda Nikolaos A Trikalinos Shagufta Shaheen Namrata Vijayvergia Arvind Dasari Jonathan R Strosberg Elise C Kohn Matthew H Kulke Eileen M O'Reilly Jeffrey A Meyerhardt

Networks:: CA824, FL065, HAWAII, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY016, LAPS-OH007, NY021

Study: Alliance-A021602
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: